 Patient-derived xenograft, PDX, models are becoming increasingly popular for studying cancer due to their ability to accurately replicate the genetic and biological characteristics of patient tumours. This makes them an ideal tool for preclinical testing of new treatments, drug combinations, and drug sensitivity are resistant studies. Furthermore, advances in technology such as multiomics and deep learning have allowed for a more detailed understanding of the molecular landscape of these models, making them even more valuable for researchers. This article was authored by Ihan Liu, Wan Tau Wu, Cheng Jing CAI, and others.